ArticleDiscover oncology2026

Efficacy and safety of Osimertinib and other third-generation EGFR TKIs in advanced NSCLC: a systematic review and meta-analysis.

Juan Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.